IMPROVEMENT AND CHALLENGES IN UNDERSTANDING EPILEPSY: A COMPREHENSIVE REVIEW

Pharmacy

Epilepsy is a serious neurological illness affecting around 50 million individuals globally. Almost 30% of epileptic patients have pharmacoresistance, which is linked to social isolation, dependent behaviour, poor marriage rates, unemployment, psychiatric problems, and a lower quality of life. The efficacy of currently available antiepileptic medicines is limited, and their unfavourable qualities limit their usage and create issues in patient care. Antiepileptic medicines can only provide symptomatic relief because they reduce seizures but cannot cure epileptogenesis. The long-term use of antiepileptic medications is limited due to their side effects, withdrawal symptoms, negative interactions with other drugs, and economic load, particularly in developing nations. Furthermore, several existing antiepileptic medicines may exacerbate some types of seizures. Several in vivo and in vitro animal models have been presented, and numerous novel antiepileptic medications have lately been approved, however a considerable percentage of patients remain pharmacoresistant. This study will focus on the challenges associated with epilepsy therapy and management, as well as the limits of existing antiepileptic medicines and animal seizure models.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.